276 related articles for article (PubMed ID: 27034278)
1. MicroRNAs for Restenosis and Thrombosis After Vascular Injury.
Gareri C; De Rosa S; Indolfi C
Circ Res; 2016 Apr; 118(7):1170-84. PubMed ID: 27034278
[TBL] [Abstract][Full Text] [Related]
2. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
[TBL] [Abstract][Full Text] [Related]
3. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
Zhao FH; Chen YD; Jin ZN; Lu SZ
Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
[TBL] [Abstract][Full Text] [Related]
4. Novel potential targets for prevention of arterial restenosis: insights from the pre-clinical research.
Forte A; Rinaldi B; Berrino L; Rossi F; Galderisi U; Cipollaro M
Clin Sci (Lond); 2014 Dec; 127(11):615-34. PubMed ID: 25072327
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of coronary artery restenosis.
Schwartz RS; Henry TD
Rev Cardiovasc Med; 2002; 3 Suppl 5():S4-9. PubMed ID: 12478229
[TBL] [Abstract][Full Text] [Related]
6. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
7. PERK Inhibition Promotes Post-angioplasty Re-endothelialization via Modulating SMC Phenotype Changes.
Wang B; Zhang M; Urabe G; Shirasu T; Guo LW; Kent KC
J Surg Res; 2021 Jan; 257():294-305. PubMed ID: 32871430
[TBL] [Abstract][Full Text] [Related]
8. PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design.
Holy EW; Jakob P; Eickner T; Camici GG; Beer JH; Akhmedov A; Sternberg K; Schmitz KP; Lüscher TF; Tanner FC
Eur Heart J; 2014 Mar; 35(12):808-20. PubMed ID: 24334406
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
Ducrocq G; Serebruany V; Tanguay JF
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
[TBL] [Abstract][Full Text] [Related]
10. Stent thrombosis in the era of drug eluting stents.
Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
[TBL] [Abstract][Full Text] [Related]
11. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
12. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam".
O'Sullivan JF; Martin K; Caplice NM
J Am Coll Cardiol; 2011 Jan; 57(4):383-9. PubMed ID: 21251577
[TBL] [Abstract][Full Text] [Related]
13. Ghrelin could be a candidate for the prevention of in-stent restenosis.
Shu ZW; Yu M; Chen XJ; Tan XR
Cardiovasc Drugs Ther; 2013 Aug; 27(4):309-14. PubMed ID: 23512274
[TBL] [Abstract][Full Text] [Related]
14. Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis.
Torrado J; Buckley L; Durán A; Trujillo P; Toldo S; Valle Raleigh J; Abbate A; Biondi-Zoccai G; Guzmán LA
J Am Coll Cardiol; 2018 Apr; 71(15):1676-1695. PubMed ID: 29650125
[TBL] [Abstract][Full Text] [Related]
15. Drug-eluting versus bare-metal coronary stents: where are we now?
Amoroso NS; Bangalore S
J Comp Eff Res; 2012 Nov; 1(6):501-8. PubMed ID: 24236469
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
17. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation.
Iaccarino D; Politi L; Rossi R; Sgura F; Monopoli D; Modena MG; Sangiorgi GM
J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):536-43. PubMed ID: 20090547
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Rossini R; Musumeci G; Aprile A; Valsecchi O
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):49-61. PubMed ID: 20121564
[TBL] [Abstract][Full Text] [Related]
20. Endothelialization and in-stent restenosis on the surface of glycoprotein IIIa monoclonal antibody eluting stent.
Yin TY; Wang GX; Zhang DC; Du DY; Li ZG; Luo LL; Hou YB; Wang YZ; Zhao JB
J Biomed Mater Res A; 2012 Jun; 100(6):1398-406. PubMed ID: 22374816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
